Sei Investments Co. Has $25.35 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Sei Investments Co. increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 48.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 761,209 shares of the biotechnology company’s stock after purchasing an additional 248,165 shares during the quarter. Sei Investments Co. owned approximately 0.27% of Exelixis worth $25,350,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Quantbot Technologies LP increased its stake in shares of Exelixis by 93.0% in the fourth quarter. Quantbot Technologies LP now owns 11,092 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 5,344 shares during the period. Magnetar Financial LLC bought a new stake in Exelixis in the fourth quarter valued at approximately $448,000. Teacher Retirement System of Texas boosted its holdings in Exelixis by 15.6% in the fourth quarter. Teacher Retirement System of Texas now owns 76,017 shares of the biotechnology company’s stock valued at $2,531,000 after acquiring an additional 10,264 shares during the last quarter. Harvest Fund Management Co. Ltd acquired a new stake in Exelixis during the 4th quarter valued at approximately $440,000. Finally, Intech Investment Management LLC raised its holdings in Exelixis by 15.4% during the 4th quarter. Intech Investment Management LLC now owns 267,725 shares of the biotechnology company’s stock worth $8,915,000 after purchasing an additional 35,684 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on EXEL shares. UBS Group upped their price objective on shares of Exelixis from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Citigroup increased their price target on Exelixis from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Piper Sandler lifted their price objective on Exelixis from $37.00 to $38.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada upped their target price on Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, March 13th. Finally, Stifel Nicolaus lifted their target price on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Price Performance

NASDAQ:EXEL opened at $37.01 on Thursday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The company has a market cap of $10.36 billion, a PE ratio of 20.91, a PEG ratio of 1.13 and a beta of 0.57. The firm has a 50-day moving average of $35.69 and a 200-day moving average of $33.12.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, equities research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the sale, the director now owns 33,514 shares in the company, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by corporate insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.